Oncodesign Precision Medicine Société anonyme (EPA:ALOPM)
France flag France · Delayed Price · Currency is EUR
0.3420
+0.0010 (0.29%)
At close: Jun 23, 2026

EPA:ALOPM Income Statement

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22
Operating Revenue
0.260.221.48.02
Other Revenue
1.551.420.340.27
1.811.641.748.29
Revenue Growth (YoY)
10.87%-6.02%-79.03%-
Cost of Revenue
-6.946.5187.56
Gross Profit
8.75-4.88-6.260.73
Selling, General & Admin
2.592.593.312.08
Other Operating Expenses
0.110.080.120.1
Operating Expenses
3.052.933.692.34
Operating Income
5.71-7.81-9.94-1.61
Interest Expense
-0.19-0.44-0.15-0.12
Interest & Investment Income
0.050.30.240
Currency Exchange Gain (Loss)
-0-0-0.020
Other Non Operating Income (Expenses)
-0.02--0
EBT Excluding Unusual Items
5.55-7.95-9.86-1.72
Gain (Loss) on Sale of Investments
-0.04-0.020.01-
Other Unusual Items
0-0.350-0
Pretax Income
5.51-8.31-9.85-1.72
Income Tax Expense
0.03-1.1-1.76-1.49
Net Income
5.48-7.21-8.09-0.23
Net Income to Common
5.48-7.21-8.09-0.23
Shares Outstanding (Basic)
18181717
Shares Outstanding (Diluted)
18181717
Shares Change (YoY)
1.34%9.16%-0.48%-
EPS (Basic)
0.30-0.40-0.49-0.01
EPS (Diluted)
0.30-0.40-0.49-0.01
Gross Margin
482.81%-298.27%-8.84%
Operating Margin
314.83%-477.48%-571.55%-19.41%
Profit Margin
302.27%-440.94%-465.04%-2.79%
EBITDA
6.05-7.55-9.69-1.45
EBITDA Margin
333.58%---17.43%
D&A For EBITDA
0.340.260.250.16
EBIT
5.71-7.81-9.94-1.61
EBIT Margin
314.83%---19.41%
Effective Tax Rate
0.61%---
Revenue as Reported
1.811.641.758.32